|MDACC Study No:||2011-0269 (clinicaltrials.gov NCT No: NCT01375140)|
|Title:||EVALUATION OF RUXOLITINIB AND LENALIDOMIDE COMBINATION AS A THERAPY FOR PATIENTS WITH MYELOFIBROSIS|
|Principal Investigator:||Srdan Verstovsek|
|Treatment Agent:||Lenalidomide; Prednisone; Ruxolitinib|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
ruxolitinib and lenalidomide can help to control MF. The safety of this study
drug combination will also be studied.
Ruxolitinib is designed to stop certain proteins (called JAK1 and JAK2) that
are found in MF cells from sending signals that may lead to the growth of
Lenalidomide is designed to change the body's immune system. It may also
interfere with the development of tiny blood vessels that help support tumor
growth. This may decrease the growth of cancer cells.